Similarly, a combination therapy, comprising PF‐04136309, a CCR2 inhibitor with FOLFIRINOX, achieved generated effective tumor response and achieved local tumor control in 97% of patients with pancreatic cancer.170. The gene discussed is CCR2; the disease is neoplasm.